title: Elevated drug saliva levels suggest a "depot-like" effect in subjects treated with sublingual buprenorphine.
authors.affiliation: National Institute on Drug Abuse, Addiction Research Center, Baltimore, MD 21224.
authors.forename: E J
authors.initials: EJ
authors.lastname: Cone
authors.forename: S L
authors.initials: SL
authors.lastname: Dickerson
authors.forename: W D
authors.initials: WD
authors.lastname: Darwin
authors.forename: P
authors.initials: P
authors.lastname: Fudala
authors.forename: R E
authors.initials: RE
authors.lastname: Johnson
mesh_terms: D000286:Administration, Sublingual; D002047:Buprenorphine / Q000008:administration & dosage / Q000493:pharmacokinetics*; D003692:Delayed-Action Preparations; D006801:Humans; D012463:Saliva / Q000737:chemistry*
chemical_list: D003692:Delayed-Action Preparations; D002047:Buprenorphine